Mindset Pharma Strengthens IP Portfolio with Another New Provisional Patent Application Covering its Next-Generation DMT and 5-MeO-DMT Drug Candidate Compounds Post published:April 19, 2022 Post category:Press Release
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions Post published:February 17, 2022 Post category:Press Release
Mindset Pharma Appoints Dr. Fiona Randall as Senior Vice President of External Alliances and Scientific Strategy Post published:February 8, 2022 Post category:Press Release
Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its “Microdosing” Compounds Post published:February 3, 2022 Post category:Press Release
Mindset Pharma Enters Manufacturing Agreement with Leading CDMO to Produce Pharmaceutical Grade Batches of Next-Generation Psilocybin Drug Candidate, MSP-1014 Post published:January 25, 2022 Post category:Press Release
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines Post published:January 5, 2022 Post category:Press Release
Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation Psychedelics at Neuroscience 2021 Post published:November 8, 2021 Post category:Press Release
Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions Post published:October 14, 2021 Post category:Press Release
Mindset Pharma Expands Pipeline: Identifies Additional Next Generation 5-MeO-DMT-Inspired Lead Candidates Post published:September 29, 2021 Post category:Press Release
Mindset Pharma Announces Further Preclinical Results Demonstrating Strong Efficacy and Improved Safety Profile for its 5-MeO-DMT-Inspired Drug Candidate, MSP-4018 Post published:September 20, 2021 Post category:Press Release